On Oct. 25, 2018, The Foundation for the National Institutes of Health, Biomarkers Consortium and the Critical Path Institute Predictive Safety Testing Consortium (PSTC) announced they had received the first ever qualification of a clinical safety biomarker awarded by the U.S. Food and Drug Administration (FDA) – a major milestone that will improve the detection of drug-induced kidney injury in early phase drug development.